NCT05062174View on ClinicalTrials.gov

Breast Cancer BRCA1 Carriers: a Pilot Study

WithdrawnOBSERVATIONAL
0
Timeline

Start Date

November 1, 2021

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2024

Conditions
BRCA1 MutationHigh-grade Serous Ovarian CancerTNBC - Triple-Negative Breast Cancer
Interventions
DRUG

Mifepristone 200 MG

Orally, one time dosage of 200 mg

PROCEDURE

Prophylactic mastectomy

Planned prophylactic mastectomy (having one or both breasts removed).

Trial Locations (2)

46032

IU Health Joe and Shelly Schwarz Cancer Center, Carmel

46202

Indiana University Melvin & Bren Simon Cancer Center, Indianapolis

Sponsors
All Listed Sponsors
collaborator

Breast Cancer Research Foundation

OTHER

lead

Indiana University

OTHER